Ligand Pharmaceuticals Inc expected to post earnings of 64  cents a share - Earnings Preview

Ligand Pharmaceuticals Incorporated

05/08/2023 03:03

* Ligand Pharmaceuticals Inc  LGND.OQ   LGND.O  is expected
to show a fall in quarterly revenue when it reports  results on
August 8. 
    * The San Diego California-based  company is expected to
report  a
55.2% decrease in revenue to $25.733 million from $57.42 million
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Ligand
Pharmaceuticals
Inc is for earnings of 64 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ligand
Pharmaceuticals Inc is $103.5​, above​ its last closing price
of $66.79. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  0.95        0.89       2.28      Beat    155
 Dec. 31 2023  1.18        1.19       1.36      Beat    14
 Sep. 30 2022  0.44        0.43       1.31      Beat    203.4​
 Jun. 30 2022  0.46        0.43       1.03      Beat    139.5
 ​​Mar.        0.66        0.66       0.58      Missed  -11.7
 31 2022                                                
 Dec. 31 2021  1.37        1.37       1.80      Beat    31.4​
 Sep. 30 2021  1.02        1.04       1.58      Beat    52.4
 Jun. 30 2021  1.34        1.36       1.63      Beat    19.7
 This summary was machine generated August 5 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated